3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Renal Cell
7
Sarcoma
5
Melanoma
5
Lymphoma, Non-Hodgkin
5
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Neoplasms
4
Endometrial Neoplasms
4
Carcinoma, Hepatocellular
4
Neoplasm Metastasis
3
Multiple Myeloma
3
Lymphoma, Large B-Cell, Diffuse
3
Leukemia, Myeloid, Acute
3
Kidney Neoplasms
3
Glioblastoma
3
Squamous Cell Carcinoma of Head and Neck
2
Rhabdomyosarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Lymphoma, Mantle-Cell
2
Liver Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hodgkin Disease
2
Fallopian Tube Neoplasms
2
Congenital Abnormalities
2
Breast Neoplasms
2
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Interventions
Specimen Handling
3
Nivolumab
3
olaparib
2
durvalumab
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
CTLA-4 Antigen
2
temsirolimus
1
serabelisib
1
sapanisertib
1
rucaparib
1
copanlisib
1
ceralasertib
1
cediranib
1
capivasertib
1
cabozantinib
1
Paclitaxel
1
Immunoglobulin G
1
Fluid Therapy
1
Disulfides
1
Carboplatin
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Endometrioid
×
temsirolimus
×
Clear all
NCT02093598
2020-11-27
POEM
MedSIR
Phase 2
Completed
10 enrolled